Premium
Imidazoline Receptor Agonist Drugs: A New Approach to the Treatment of Systemic Hypertension
Author(s) -
Yu Austin,
Frishman William H.
Publication year - 1996
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1996.tb04174.x
Subject(s) - imidazoline receptor , moxonidine , rilmenidine , pharmacology , agonist , neuroprotection , medicine , clonidine , blood pressure , receptor , central nervous system
The imidazoline receptors have recently been discovered to be involved in central nervous system control of blood pressure (I‐1 receptor) and in neuroprotection for cerebral ischemia (I‐2 receptor). A new class of central‐acting antihypertensive agents has been developed, the imidazoline receptor agonists (rilmenidine and moxonidine), which control blood pressure effectively without the adverse effects of sedation and mental depression that are usually associated with central‐acting antihypertensives. This new generation of central‐acting antihypertensive agents are highly selective for the imidazoline receptor, while having a low affinity for α 2 ‐adrenergic receptors.